Compare prices and buy AOD-9604 from 32 research peptide vendors - also called suppliers or sources. Updated daily.
A 16-amino-acid synthetic peptide (CAS 221231-10-3) reproducing residues 177-191 of human growth hormone, the C-terminal region linked to its fat-mobilizing activity, preceded by a tyrosine. Studies in obese mice reported increased fat oxidation and energy expenditure. Its developer, Metabolic Pharmaceuticals, ended the obesity program after the largest trial missed its primary endpoint, and it is not FDA-approved as a drug.
For research purposes only. Not medical advice.
AOD-9604 is a 16-residue synthetic peptide, CAS 221231-10-3, molecular formula C78H123N23O23S2, closed by a disulfide bridge between its seventh and fourteenth residues. It reproduces the C-terminal end of human growth hormone, residues 177 to 191, preceded by a tyrosine. Metabolic Pharmaceuticals developed it as AOD-9604, and Lateral Pharma later renamed the same molecule LAT8881.
It is neither a secretagogue nor an incretin. Sermorelin, tesamorelin, CJC-1295 and ipamorelin prompt the pituitary to release its own growth hormone, whereas AOD-9604 is a piece of the hormone itself, and in a 2001 cell assay it did not displace growth hormone from its receptor. It sits beside semaglutide and retatrutide here on commercial grounds, not mechanistic ones.
HGH Frag 176-191 is catalogued separately, and vendor copy routinely treats the two as one product. The native fragment starts at residue 176 with a phenylalanine. AOD-9604 substitutes tyrosine for it, which is why it is written Tyr-hGH(177-191) rather than as the native fragment with something added.
The molecular formulas settle it. The native fragment is C78H123N23O22S2 and AOD-9604 is C78H123N23O23S2: identical carbon, hydrogen, nitrogen and sulfur counts, and exactly one extra oxygen, the para-hydroxyl that distinguishes tyrosine from phenylalanine. Both are 16 residues. Appending a tyrosine to the 176-191 fragment would instead give a 17-residue peptide with a different formula.
Metabolic Pharmaceuticals ran six clinical studies enrolling 936 subjects, more than 700 of whom received active drug. The first two used single intravenous doses. The remaining four were oral, delivered first as capsules and finally as tablets. The program ended on the largest, METAOD006, a 24-week oral study that randomized 502 subjects, 377 of them to active drug. It did not meet its primary endpoint, and development for obesity was discontinued in 2007. A later Lateral Pharma protocol describes the program as well tolerated throughout, with a profile indistinguishable from placebo in the two long studies.
The compound stayed in development under a new indication. Three trials have completed under the LAT8881 name, all in pain:
Lateral's 2023 trial protocol reports that neither the neuropathic pain trial nor the migraine trial, both given orally, significantly reduced pain compared with placebo, and it estimates the peptide's oral bioavailability at below 1%. A 2026 paper in Pain identified the target behind that work as lanthionine synthetase C-like protein 1.
FDA has never approved AOD-9604. It placed the peptide in Category 2 of its interim 503A bulk drug substances list, the designation for substances the agency says may present significant safety risks, then removed it from that category in September 2024, alongside CJC-1295, ipamorelin acetate and thymosin alpha-1, after the parties that had nominated them withdrew their nominations. Selank acetate left Category 2 in the same update for a different reason.
That removal did not end the review. FDA's briefing document records two nominations, from Wells Pharmacy and the International Peptide Society, both withdrawn, and states that the agency evaluated AOD-9604 on its own initiative before consulting the Pharmacy Compounding Advisory Committee. The committee heard AOD-9604 on December 4, 2024, agreed unanimously to poll the free base and the acetate as a single question, and rejected both, with none in favor and twelve against.
The September removal itself was administrative and implies no safety finding, but FDA keeps the original safety text attached to the withdrawn entry. AOD-9604's still reads immunogenicity risk for certain routes of administration, complexity around peptide-related impurities and characterization of the active ingredient, no or only limited safety information, and serious adverse events that may be associated with the compound though causality is not clear.
AOD-9604 is prohibited in sport at all times. The World Anti-Doping Agency's 2026 Prohibited List names it under S2.2.3, growth hormone analogues and fragments, on the same line as hGH 176-191. That listing treats the two as distinct substances. A validated urine detection method appeared in Drug Testing and Analysis in 2015, a year after the same journal reported the peptide identified in preparations seized by Belgian authorities.
Listings are usually plain "AOD-9604" or the shorthand "AOD," with "AOD9604" and the transposed "AOD-9064" both in circulation. It is sold mainly as lyophilized injectable vials, which inverts the clinical record: every obesity study after the first two was oral, and the 24-week Phase 2b trial used tablets. PeptideScouter indexes vial listings per milligram and verifies identity against the published CAS number rather than the product title.
No, and they are catalogued as separate rows here. HGH Frag 176-191 is the native C-terminal fragment of human growth hormone and begins with phenylalanine. AOD-9604 substitutes tyrosine for that residue, which makes it Tyr-hGH(177-191). Both are 16 residues long, and their molecular formulas differ by exactly one oxygen atom: C78H123N23O22S2 for the native fragment against C78H123N23O23S2 for AOD-9604. The World Anti-Doping Agency lists the two as separate examples of prohibited growth hormone fragments.
Metabolic Pharmaceuticals ran six clinical studies enrolling 936 subjects, more than 700 of whom received active drug. The largest, METAOD006, was a 24-week oral study that randomized 502 subjects, 377 of them to active drug, and it did not meet its primary endpoint. Development for obesity was discontinued in 2007. Safety was not the reason: a later trial protocol describes the program as well tolerated throughout, with a profile indistinguishable from placebo in the two long studies.
No. FDA has never approved AOD-9604. It placed the peptide in Category 2 of its interim 503A bulk drug substances list, the designation for substances the agency says may present significant safety risks, and removed it from that category in September 2024, after the nominations were withdrawn. The Pharmacy Compounding Advisory Committee reviewed it anyway on December 4, 2024 and voted against adding it, none in favor and twelve against. Material sold by research vendors is research-grade and offered for laboratory use only, not for human consumption.
The same peptide under a later code. Metabolic Pharmaceuticals developed it as AOD-9604 for obesity, and after that program ended in 2007 Lateral Pharma took it forward as LAT8881, redirected at pain rather than metabolism. Three trials have completed under that name: a Phase 2a in neuropathic pain, a Phase 2 crossover in acute migraine, and a two-part Phase 1 in lumbar radicular pain. A 2026 paper in the journal Pain identified the binding target behind that work as lanthionine synthetase C-like protein 1.
Yes, at all times rather than only in competition. The World Anti-Doping Agency's 2026 Prohibited List includes AOD-9604 in section S2.2.3, covering growth hormone and its analogues and fragments, naming it on the same line as hGH 176-191. A validated urine detection method for the peptide was published in the journal Drug Testing and Analysis in 2015, a year after the same journal reported it identified in pharmaceutical preparations seized by Belgian authorities.
AOD-9604 is sold by 32 research peptide vendors indexed on PeptideScouter, with 50 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
29 of the 32 indexed vendors currently have AOD-9604 in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
NextGen Peptide currently lists AOD-9604 at $5.50/mg, the lowest listed price across 32 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $3.60/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 32 vendors listing AOD-9604 publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $4.00/mg listed to $3.60/mg at NextGen Peptide. Each vendor's code is shown beside its price in the table above.
AOD-9604 ranges from $4.00/mg to $19.00/mg across 50 listings from 32 research peptide vendors, normalized to USD per milligram and refreshed daily.
32 research peptide vendors currently list AOD-9604 on PeptideScouter, with 29 in stock right now. We track 50 listings across size and kit variants.
AOD-9604's CAS Registry Number is 221231-10-3. It is also sold as AOD, AOD-9064, AOD9604.
